ESR1 and neoplasm: Thus, existing evidence supports the postulate that enhanced secretion of PTHrP mediated by ERα in ER+ tumor cells disseminated to bone, as documented here, may be one specific pathway driving E2 dose-dependent tumor osteolysis and osteolytic ER+ BMET progression documented in vivo.